What KPV Adds to the Repair & Recovery Stack
Of the peptides in this category, KPV is the one almost nobody has heard of, and it is the one with the clearest logic for being in a stack. It is not aimed at building tissue. It is aimed at the inflammation that sits on top of an injury, which is a different job from what the repair peptides are explored for.
Whether it does that job in a person is a question the research has not answered. The preclinical work is interesting and narrow, the human work does not exist yet, and the regulatory standing is the same unsettled picture that covers this whole group of substances. All three parts are below.
What KPV is
KPV is as small as a peptide gets and still have a name. It is three amino acids — lysine, proline and valine — and the letters are simply their single-letter codes.
Those three are the tail end of alpha-melanocyte-stimulating hormone, a hormone the body makes. Alpha-MSH is best known for its role in pigmentation, but it also has a well-described anti-inflammatory side, and research going back decades established that the anti-inflammatory activity is concentrated in that final three-amino-acid sequence. KPV is that sequence on its own: the part that calms inflammation, separated from the part that affects pigment.
That is a more elegant origin than most peptides in this space have. It is a known hormone, a known activity, and a defined fragment carrying the part you want.
What the research covers
Almost all of it is preclinical, and most of it is about the gut.
The heaviest body of work uses mouse models of colitis — chemically induced inflammatory bowel disease, the standard laboratory stand-in for ulcerative colitis and Crohn's disease. Across those models, KPV has been reported to reduce inflammatory markers and limit tissue damage compared with no treatment.
A notable strand of that work is about delivery rather than the molecule. Several groups have studied ways to get KPV to inflamed intestinal tissue specifically — nanoparticle carriers, hydrogels, formulations designed to survive the upper digestive tract — which is a signal that delivery is a genuine obstacle rather than a solved problem.
The mechanism most often proposed is that KPV is taken up by a peptide transporter present on intestinal lining cells and on immune cells, and that once inside it interferes with the signaling pathways that drive inflammatory gene expression.
There is a smaller literature on skin and wound inflammation, including topical applications. It is early.
What there is not, as of this writing, is a published randomized controlled trial of KPV in humans for any condition. Not for gut inflammation, not for recovery, not for skin.
What it is supposed to add to a stack
The reasoning is about division of labor.
The tissue-repair peptides in this category are explored for the building side of healing — blood supply, growth signals, the movement of cells into a damaged area. KPV is explored for the opposite side: turning down the inflammatory response that accompanies injury. In principle, a combination covers both, and neither component is doing the other's job redundantly.
Two honest qualifications belong immediately next to that.
Inflammation is part of healing, not only an obstacle to it. The inflammatory phase of repair clears debris and recruits the cells that rebuild tissue. Suppressing it is not automatically an improvement, and the assumption that less inflammation means better recovery is exactly the kind of thing that needs testing rather than asserting. This is not a hypothetical concern — it is the reason the role of anti-inflammatory drugs in tendon and muscle healing has been argued over for years.
No trial has tested the combination. As with every stack in this category, the components have been studied separately, in animals, and no published study compares the combination against its individual parts. Whatever KPV adds, nobody has measured it in a stack, and certainly not in people.
So the case for including KPV is a mechanistic case. It is a better mechanistic case than most. It is still a mechanistic case, and the Wolverine Stack comparison makes the same point about a different pairing for the same reason.
Where KPV stands with the FDA
KPV is not an FDA-approved drug.
It was one of the twelve peptide substances the FDA removed from Category 2 of the interim 503A bulk substances list in April 2026. That removal followed the nominators withdrawing their nominations rather than any safety determination, and it did not by itself authorize compounding.
In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend KPV for the 503A Bulks List, by eight votes to six with one abstention, against FDA staff's own recommendation. That vote is advice to the agency. Formal addition requires notice-and-comment rulemaking, which has not been completed, so nothing has formally changed. The position is unsettled and is being revisited, and the BPC-157 regulatory status page lays out the sequence in full.
What a reader should take from this
KPV is a small fragment of a real hormone, with a coherent anti-inflammatory rationale, a respectable preclinical literature concentrated in gut inflammation models, an unsolved delivery problem, no human trials, and a regulatory standing that is in motion.
That is a more honest summary than the phrase on the front of most stacks. And if you have inflammatory bowel disease, the most important sentence on this page is that the condition has approved treatments with large randomized trials behind them, and a peptide studied in mice is not a substitute for a gastroenterologist.
Frequently asked questions
A three-amino-acid peptide — lysine, proline, valine — that makes up the tail end of alpha-melanocyte-stimulating hormone. The anti-inflammatory activity of that hormone is attributed to this fragment, which is why it is studied on its own.
It is the anti-inflammatory component rather than a tissue-building one. The idea is that it addresses a different part of recovery than the repair peptides do. No study has confirmed it adds anything in a combination.
No published randomized controlled trial in humans, for any use. The research is preclinical and concentrated in mouse models of gut inflammation.
It is a fragment of a hormone the body already makes, which is reassuring in theory and is not evidence. There is no long-term human safety data, and short-term human data is essentially absent.
No. It was removed from Category 2 of the FDA's interim 503A list in April 2026 and recommended by an advisory committee in July 2026, but the rulemaking that would change its standing has not been completed.
No. Inflammatory bowel disease has approved therapies supported by large trials, and stopping them carries real risk of disease progression. Any change belongs with the specialist managing it.
Where this fits in your plan
If recovery is the goal, the measurable things come first — a baseline panel including inflammatory markers, and an honest look at sleep and training load. Then the BPC-157 evidence page for how thin this literature is overall, and the regulatory status page for where the rules sit. The peptide therapy overview covers the category.
We measure first. Then we act.
References
- Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatories. Annals of the Rheumatic Diseases 2004;63(Suppl 2):ii52–ii55.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166–178.
- Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy 2017;25(7):1628–1640.
- Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo, and future perspectives. Endocrine Reviews 2008;29(5):581–602.
- FDA. Removal of twelve substances from Category 2 of the 503A interim list, April 2026.
- FDA Pharmacy Compounding Advisory Committee. Meeting materials and voting record, 23–24 July 2026.
- Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(Suppl 3):s1–s106.
- Back toRepair & Recovery Stack
- BPC-157A recovery peptide with far more discussion than proof — offered with the evidence stated plainly.Read
- Wolverine Stack vs BPC-157 aloneAdding TB-500 to BPC-157 is meant to attack repair from a second direction. No trial has ever compared the pair to either one on its own.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
Inflammatory bowel disease should be managed by a qualified clinician.